EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes

SCHOTT Pharma see FY 25 impacted by slower growth from syringes

For its fiscal year 2024/2025, beginning 1^st October 2024, the company is forecasting a revenue growth in a high single-digit to a low double-digit percentage range, which deviates from the current market consensus. Due to the revenue growth that is lower than previously expected, the EBITDA margin expansion will be weaker than currently expected in the market.

These forecasts are based on constant currencies.

The reason for the expected development in fiscal year 2024/2025 is a lower demand for syringes of a large customer.

Despite this temporary effect, the company confirms its mid-term forecast. The company also confirms its forecast for the current fiscal year.

Investor contact

Jasko Terzic, CFA

Senior Investor Relations Manager

E-Mail: ir.pharma@schott.com

Press contact

Joana Kornblum

Media Relations

Tel.: +49 151/29223552

E-Mail: joana.kornblum@schott.com